🔎 Trials Near Me

Home › Quitting Smoking › NCT07166120

Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients

Recruiting

Who can join

Ages 18 to 89 · All sexes

Full eligibility criteria
Eligibility Criteria for Clinicians:

* Clinician from participating oncology/hematology clinic
* At least 18 years of age
* Can speak and understand English

Inclusion Criteria for Patients:

* Patient at participating clinic
* Age 18-89 years
* Current smoking (average cigarettes per day ≥5)
* Can speak and understand English
* Willing to consider medication to help reduce craving or smoking such as nicotine patch, lozenge, or varenicline

Exclusion Criteria for Patients:

* Active use of smoking cessation medication (within the past 30 days)
* Receipt of smoking cessation medication or prescription for smoking cessation medication (within the past 30 days)
* Having a contradiction for cNRT or varenicline (allergic reactions, current cardiac problems, pregnancy)
* Patients who were deemed by the investigator to be ineligible for participation in the trial

About the study

This study evaluates the feasibility and preliminary effects of precision tobacco treatment, compared to usual care, on promoting tobacco treatment in oncology patients and providers in the oncology care setting. The precision treatment intervention includes personalized tobacco treatment recommendations using the patient's clinical, genetic, and biomarker information. This intervention may increase patient receipt of tobacco treatment, patient medication use, and patient smoking abstinence at 6 months.

What is being tested

Sponsor: Washington University School of Medicine · Participants: 132 · Started: Sep 11, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07166120

Locations in the U.S.

MissouriJohn Cochran Veteran's Affairs Medical Center, St Louis
Washington University School of Medicine, St Louis

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.